Influenza Medication Market to Reach US$2,012.6 Mn by 2025, Globally: Transparency Market Research

Monday, January 15, 2018 Research News
Email Print This Page Comment bookmark
Font : A-A+

Global Influenza Medication Market: Increasing Spending on Immunization Programs to Bolster Growth Prospects

ALBANY, New York, January 15, 2018 /PRNewswire/ --

According to a new market report, the global Influenza Medications

Market was valued at US$ 1,699.7 Mn in 2016 and is expected to grow at a high CAGR of 1.4% from 2017 to 2025, to reach an estimated value of US$ 2,012.6 Mn in 2025.

The report on global influenza medications market has been classified on the basis of three categories by product, distribution channel type and geography (regions & countries). The product category further sub segmented into Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine, Inosine and Others (laninamivir octanoate, etc.), In term of distribution channels global influenza medications market is divided into hospitals, clinics, pharmacies and others. The report offers a detailed description behind the steady growth rate of the market and a possible growth trajectory at the global as well as regional level in terms of value and the market share for each global Influenza Medications market segment. The report is thus, compiled with the prime intent of updating the stakeholders with the incumbent market dynamics through a graphical illustration and in-depth analysis of each segment considered within the study scope.

View Report Preview at

Based on product type of global Influenza Medications market, Oseltamivir remained the key contributor towards the global market, which accounted for approximately 48.8% of the global market in 2016. Tamiflu (oseltamivir) is used for the prophylaxis and treatment of flu caused by influenza virus types A (H1N1) and B. The first generic was launched in 2016 by Natco Pharma in the U.S. During 2009's H1N1 swine flu outbreak, Tamiflu has been found to be active against it. Relenza (zanamivir) was first in a new class of antiviral flu drugs (neuraminidase inhibitors), approved for prescription in over 70 countries. Despite its better efficacy rates and lower price compared to Tamiflu, Relenza hold only small portion of anti-influenza medication market. The major drawback include the drug is administered through respiratory route thus lead to other respiratory problem and it is only approved in patients over 7 year of age. The availability of other generic influenza medications products at low cost, with increased use of other formulations such as Peramivir, Inosine and Laninamivir Octanoate are expected to gain share of the influenza medication market.

Request to View Sample of Report -

Among distribution channels, the pharmacies segment held the largest share accounting around 37.2% share of global market in 2016. Patients discharged from hospitals or clinics with an influenza treatment plan to utilize influenza medication for a prescribed treatment duration prefer online or retail pharmacy purchase. The pharmacies segment is projected to generate high sales revenue, owing to increase in the number of pharmacy stores. The hospitals segment is considered a lucrative segment with substantial market share of 29.9% in 2016. Hospitals commonly preferred distribution channel segment, as the patients with HIV and cardiovascular disease associated with Influenza. Increasing incidence of influenza in hospital in-patients drives the growth of this segment.

Download PDF Brochure of Report:

The key players operating in the global Influenza Medications market are Daiichi Sankyo Company, GlaxoSmithKline plc, Natco Pharma, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH (Novartis AG), Sun Pharmaceutical Industries Ltd., Mylan, Inc. and others. The global Influenza Medications market is fragmented with presence of few large and small scale vendors that operates global market. However, the global market is dominated by few major players.

Buy Influenza Medication Market Research Report:

About TMR 

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company's exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact Transparency Market Research State Tower 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Email: Website: TMR Blog:

SOURCE Transparency Market Research

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store